10–12 One exception was seen in Hohnloser et al reporting a slightly significant risk reduction of ischaemic stroke in case of apixaban. 23 The composite effectiveness outcome in that study indicated an even more pronounced benefit of DOACs.
← all excerpts
Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data.
1
—
—